SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model
Top Cited Papers
Open Access
- 25 March 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 371 (6536), 1374-+
- https://doi.org/10.1126/science.abf1611
Abstract
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M-pro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M-pro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M-pro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M-pro in complex with MI-23, one of themost potent compounds, revealed its interactionmode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment withMI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.Funding Information
- Department of Science and Technology of Sichuan Province (2020YFS0006)
- Department of Science and Technology of Sichuan Province (2020YFS0010)
This publication has 42 references indexed in Scilit:
- How good are my data and what is the resolution?Acta crystallographica. Section D, Structural biology, 2013
- Linking Crystallographic Model and Data QualityScience, 2012
- Features and development of CootActa crystallographica. Section D, Structural biology, 2010
- XDSActa crystallographica. Section D, Structural biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa crystallographica. Section D, Structural biology, 2009
- Synthesis and Evaluation of Keto-Glutamine Analogues as Potent Inhibitors of Severe Acute Respiratory Syndrome 3CLproJournal of Medicinal Chemistry, 2004
- Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitorBioorganic & Medicinal Chemistry Letters, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine ReplacementsJournal of Medicinal Chemistry, 1999
- On the use of the mergingRfactor as a quality indicator for X-ray dataJournal of Applied Crystallography, 1997